An observational study in Liver Cirrhosis, Hepatocellular Carcinoma and HIV, sponsored by Hospital Universitario de Valme. Completed at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Hospital Universitario de Valme · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Liver Cirrhosis with a site in Spain — 16 open to participants now, 20 under way, 3 of them phase 3. Liver Cirrhosis · Spain.
Among the 76 studies in Liver Cirrhosis with a site in Spain, this one is the 12th largest by enrollment of the 26 observational ones that give a count, is one of 5 that started in 2006, is one of 26 observational ones, and was the 32nd registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →16 of the 76 studies in Liver Cirrhosis with a site in Spain are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Spain, Austria, Belgium and 9 more countries
Ages 18+
Instituto de Investigación Marqués de Valdecilla · Sites in Spain
Ages 18–65
Boehringer Ingelheim · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
Hospital General Universitario Gregorio Marañon · Sites in Spain
Ages 50–75
The Cleveland Clinic · Sites in Spain, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 27 · Phase 3 14 · Phase 4 7
First in 1993; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 446 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 76 across the 50 interventional studies, 334 across the 26 observational. Of the 47 that completed or were terminated, 13 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 76 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario de Valme is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Hospital Universitario de Valme has 2 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Liver Cirrhosis with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT04971577Phase 3Anna CrucetaEfficacy of Simvastatin in Alcoholic Liver Fibrosis | 2027-03 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07658755Hospital General Universitario Gregorio MarañonAutomated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme | 2027-06-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 76 studies in Liver Cirrhosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective multicenter cohort recruiting consecutive patients from 7 hospitals in Andalusia, southern Spain, according to following criteria: 1) HIV infection, 2) Chronic active HCV infection, 3) Older than 18 years, 4) New diagnosis of liver cirrhosis on the basis of a liver stiffness above 14 kiloPascals, 5) No previous or concomitant decompensation of liver disease. Patients are prospectively followed-up according to a uniform protocol of care. Epidemiological, clinical and laboratory variables are periodically recorded. The primary outcomes are the emergence of a liver decompensation (including hepatocellular carcinoma), liver transplant or death. The predictors of these outcomes are analyzed.
HIV/HCV-coinfected patients diagnosed of cirrhosis on the basis of a liver stiffness equal or greater than 14 kiloPascals
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of patients who developed a first liver decompensation of cirrhosis during follow-up
Episodes of liver decompensation will include those episodes of ascites, spontaneous bacterial peritonitis, portal hypertensive gastrointestinal bleeding, hepatorrenal syndrome, hepatic encephalopathy, hepatocellular carcinoma, non obstructive jaundice and acute on chronic liver failure. These episodes will be diagnosed according to standard definitions of clinical practice guidelines in the field (i.e. HCC diagnosis will be diagnosed according to AASLD criteria, spontaneous bacterial peritonitis and hepatorenal syndrome will be diagnosed following the EASL criteria, portal hypertensive gastrointestinal bleeding according Baveno VI consensus definition,...)
Time frame: 3 years
Liver-related mortality
Probability of liver-related death after enrollment
Time frame: 3 Years
All cause mortality
Probability of death of any cause
Time frame: 3 Years
The record gives a start of Feb 2006, a primary completion of Dec 2020 and a completion of Dec 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario de Valme